Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor

Seminars in Hematology

Volumn 39, Issue 2, 2002, Pages 134-140

  Cottle, Tammy E ^a   Fier, Carol J ^a   Donadieu, Jean ^a   Kinsey, Sally E ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Plaza 600 Building   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; BONE PAIN; CHRONIC DISEASE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GLOMERULONEPHRITIS; HEPATOMEGALY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SPLENOMEGALY; THROMBOCYTOPENIA; VASCULITIS;

EID: 0036216695     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2002.31914     Document Type: Article

References (27)

1. Clinical efficacy of recombinant human granulocyte colony stimulating factor (r-metHuG-CSF) in patients with severe chronic neutropenia
2. Long-term safety of treatment with recombinant human granulocytic colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias
3. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis
4. Administration of rmetHuG-CSF during pregnancy in patients with severe chronic neutropenia (SCN)
5. Recombinant human granulocyte-colony-stimulating factor in the treatment of patients with neutropenia
6. Assessment of transplacental passage of recombinant human granulocyte colony-stimulating factor in women with an imminent preterm delivery
7. A randomized pilot trial of administration of granulocyte colony-stimulating factor to women before preterm delivery
8. Transplacental passage of recombinant human granulocyte colony-stimulating factor in women with an imminent preterm delivery
9. Hematopoietic growth factors for the treatment of severe chronic neutropenia. Concise review
10. A randomized controlled phase III trial of recombinant human G-CSF for treatment of severe chronic neutropenia
11. A European phase II study of recombinant human granulocyte colony-stimulating factor (rHuG-CSF; Lenograstim) in the treatment of severe chronic neutropenia in children
12. Second neoplasia and mortality in congenital neutropenia: Data from the French severe chronic neutropenia register
13. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor
14. Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia
15. Recombinant human granulocyte colony-stimulating factor in cyclic neutropenia: Use of a new 3-day-a-week regimen
16. Granulocyte colony-stimulating factor crosses the placenta and stimulates fetal rat granulopoiesis
17. Maternal administration of granulocyte colony-stimulating factor improves neonatal rat survival after a lethal group B streptococcal infection
18. Correction of infantile agranulocytosis (Kostmann's syndrome) by allogeneic bone marrow transplantation
19. Severe congenital neutropenia unresponsive to G-CSF
20. Lack of alterations in the cytoplasmic domains of the granulocyte colony-stimulating factor receptors in eight cases of severe congenital neutropenia
21. Recombinant human granulocyte colony stimulating factor: Effects on normal and leukemic myeloid cells
22. Recombinant human granulocyte colony stimulating factor: Effects on hematopoiesis in normal and cyclophosphamide-treated primates
23. Severe chronic neutropenia: Pathophysiology
24. Pathophysiology and treatment of severe chronic neutropenia
25. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia
26. Severe congenital neutropenia: Clinical effects and neutrophil function during treatment with granulocyte colony-stimulating factor
27. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation